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The Role of Prolactin in Autoimmune 
Demyelination: Suppression of Experimental 
Allergic Encephalomyelitis by Bromocriptine 
Peter N. Riskind, MD, PhD, Luca Massacesi, MD, Teresa H. Doolittle, PA-C, MHP, 
and Stephen L. Hauser, MD 
Several lines of evidence suggest that the anterior pituitary hormone prolactin has a stimulatory roIe on immune 
function and that pharmacological suppression of prolactin secretion with the dopamine-agonist bromocriptine 
suppresses both humoral and cellular immunity. Here, we describe the effects of prolactin-suppression on the course 
of experimental allergic encephalomyelitis in female Lewis rats. Initiation of continuous bromocriptine treatment 
before immunization reduced both the severity and incidence of clinical signs of acute experimental allergic encephalo- 
myelitis. Experimental allergic encephalomyelitis-immunized rats experienced a threefold rise in basal prolactin levels 
on day 4 after immunization and maintained elevated prolactin levels on day 10, before the onset of neurological signs 
of experimental allergic encephalomyelitis. Bromocriptine treatment reduced prolactin levels to those of sham- 
immunized rats. In viva bromocriptine pretreatment inhibited splenic lymphocyte proliferative responses in vitro to 
the immunizing antigen and to concanavalin A. Moreover, bromocriptine therapy was protective when initiated 1 
week after the initial immunization and was also effective in suppression of late disease. These results indicate that 
(1) prolactin levels are elevated after immunization and before the onset of experimental allergic encephalomyelitis, 
(2) bromocriptine inhibits both prolactin secretion and the severity of acute experimental allergic encephalomyelitis, 
and (3) inhibition is also present when treatment is begun after sensitization, suggesting an effect of prolactin on the 
effector limb of the immune response during experimental allergic encephalomyelitis. 
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Prolactin (PRL), the major hormonal stimulus to lacta- 
tion, is a 24-kd polypeptide hormone that is synthe- 
sized and secreted by the anterior pituitary gland. The 
importance of P R L  to normal immune homeostasis was 
first shown by Nagy and Berczi 111, who found that 
hypophysectomized rats were severely immunocom- 
promised, with profoundly depressed antibody titers 
to administered antigen and virtually absent delayed 
hypersensitivity responses. Surprisingly, in such ani- 
mals, immunocompetence could be restored by exoge- 
nous PRL, and to a lesser extent by growth hormone, 
but not by other pituitary hormones 121. Later work 
demonstrated that bromocriptine (BCR), a dopaminer- 
gic agonist that selectively inhibits PRL release, mimics 
the effect of hypophysectomy {33. Treatment with PRL 
reversed the effect of BCR, indicating that its activity 
was due to specific inhibition of PRL release. 
Other studies indicated that excessive PRL levels 
maj7 stimulate immune responses. PRL treatment of 
normal mice resulted in a dose-dependent increase in 
splenic cell responses to mitogens such as concanavalin 
A (ConA) [4,  S}. In rodent splenic lymphocytes, PRL 
also induced the expression of interleulun-2 receptors 
and promoted secretion of interferon gamma {4, 6). 
Sheep red blood cell responses were enhanced by PRL 
administered at the time of or  4 days after immuniza- 
tion, suggesting an effect on both the afferent and ef- 
ferent limbs of the immune response {7}. These effects 
may be due to a direct action of PRI, on lymphocytes 
as both T and B lymphocytes were found to have high- 
affinity receptors for PRL, and in the rat, the number 
of receptors per cell was similar for lymphocytes and 
mammary gland cells [S, 91. In studies of human lym- 
phocytes, binding of the drug cyclosporine could be 
reversibly displaced by PRL., suggesting that cyclo- 
sporine-induced immunosuppression may be in part 
mediated by interaction with the PRL receptor [91. 
Modulation of PRL secretion represents one poten- 
tial approach to the control of disease states character- 
ized by heightened immune reactivity, including auto- 
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Table 1. The Effect of BCR Treatment Initiated 2 Days Before Immunization on the Course of Acute E A E  
Peak Clinical 
EAE Score Neurological Day of Onset Duration 
Treatment (Mean L SEM)" Signs (Mean f SEM) (Mean * SEM) Deaths 
Control 3.4 2 0.5 loi l l  12.8 2 0.03 5.5 2 0.P 2/11 
BCR 1.4 & 0.5' 5/11d 12.8 k 0.08 4.8 * 0.5 0/11 
"Calculated as the highest EAE score for each rat during the acute illness. Unaffected cats received a score of zeru. 
bExcluding 2 rats that died during their acute illness. 
' p  < 0,001, Mann-Whitney U test. 
Clinical scores were recorded daily by a blinded observer. Data are the results of two experiments, in each of which a treatment effect was 
observed (n = 1 ligroup). 
BCR = bromocriptine; EAE = experimental allergic encephalomyelitis 
< 0.05, Fisher exact probability test. 
immune diseases. In  vitro, BCR has been shown to 
reduce lymphocyte responses to mitogens [4],  anti- 
body responses [7], and mixed lymphocyte reactivity 
181. I n  vivo, BCR pretreatment inhibited graft versus 
host disease in rats 181, and a preliminary report indi- 
cated a possible effect of BCR on  experimental allergic 
encephalomyelitis (EAE) [3}. In the current report, we  
show that BCR treatment modifies the clinical course 
of acute rat EAE, inhibits the development of late re- 
lapses, and blocks the rise of PRL levels that is present 
in control immunized animals. 
Methods 
Induction of EAE 
Adult (60-day-old) female, random-cycle Lewis rats (Charles 
River, Wilmington, MA, or Harlan Sprague Dawley, Madi- 
son, WI) were housed in a temperature-controlled (22 + 
1°C) and light-controlled room (lights on from 7 AM to 7 
PM) with food and water freely available. Rats were im- 
munized with 200 mg of guinea pig spinal cord homog- 
enate (GPSC) (Pel-Freez, Rogers, AR), previously frozen at 
- 80"C, in complete Freund's adjuvant (CFA) supplemented 
with 1 mgiml H37Ra (mycobacterium tuberculosis) or 
sham-immunized with an equal volume of sterile saline. Bilat- 
eral intraderrnal injections were made over the dorsum, in 
accordance with the recommendations of the Subcommittee 
for Animal Care at Massachusetts General Hospital (Charles- 
town, MA). 
Clinical EAE scores were graded daily by the following 
standard scoring system: 0, no neurological signs; 1, dimin- 
ished tone and paresis of the tail; 2, weak hind limbs; 3 ,  
plegic hind limbs; 4, quadriparesis; and 5 ,  death. A value of 
0.5 was added for incontinence. Rats were graded according 
to the highest single score attained, without addition of 
scores. 
BCR Treatment 
Rats were lightly anesthetized with ether for subcutaneous 
implantation of a single pellet containing either BCR or a 
control pellet (Innovative Products of America, Toledo, 
OH). The BCR pellets were designed to continuously release 
the drug at a rate of 2.3 rng/day for 21 days 141. Control 
pellets contained the same carrier binder as the BCR pellets 
(cholesterol, stearate, phosphates, a-lactose, and other pro- 
prietary ingredients). 
Measurement of Prolactin Levels 
Serum PRL levels were measured from trunk blood and from 
pituitary extracts in duplicate by radioimmunoassay (RIA), 
using materials provided by the National Institute of Diabe- 
tes, Digestive and Kidney Diseases, as previously reported 
{lo}. Pituitary extracts were prepared by sonicating each pi- 
tuitary in 1 ml of 0.65 M borate buffer, pH 9.0, centrifuga- 
tion at 15,000 g for 10 minutes, and decantation of the  super- 
natant. The sensitivity of the RIA is less than 0.25 ng/ml. 
Intra-assay and interassay coefficients of variation are less 
than 59%. 
Proliferative Assays 
Spleens from killed rats (n = 7/group) were aseptically re- 
moved and mechanically dispersed. Splenic lymphocytes 
were pooled and isolated by Ficoll-gradient centrifugation 
(Pharmacia, Piscataway, NJ). Cells were plated in triplicate 
in 96-well plates at a concentration of 2 x lo5 cellsiwell, 
with medium consisting of RPMI 1640 (GIBCO, Grand 
Island, NY), suppiemented with 5% heat-inactivated fetal 
calf serum (GIBCO), 1% L-glutarnine, 19% NaPyruvate 
(GIBCO), 1,25% HEPES buffer (GIBCO), 1% nonessential 
amino acids, 1% penicillin-streptomycin (GIBCO), and 5 x 
M 2-mercaptoethanol. Additionally, GPSC (0.19%) or 
ConA (5 (*g/ml) (Sigma Chemical, St Louis, MO) were in- 
cluded in the medium. After 80 hours of incubation, 
E3H)thymidine was added for another 16 hours of incuba- 
tion, cells were harvested, and thymidine incorporation was 
measured in a scintillation counter. The proliferative re- 
sponse was expressed as counts per minute (cpm), and as 
stimulation indices (SI), defined as the stimulated culture 
counts per minute divided by the unstimulated culture counts 
per minute. 
Results 
Bromocriptine Therapy Moderutes Acate EAE 
Typical signs of EAE appeared in nearly 100% of im- 
munized (but otherwise untreated) rats between day 
12 and day 16 after immunization. A clinical EAE score 
of 3 or greater was present in most rats and was fol- 
lowed by gradual recovery within 1 week (Table 1). 
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The eflect of bromocrzptine (BCR) pretreatment on the severity 
of experimental allergic encephalomyelitis (EAE). Rats were sub- 
cutaneous4y implanted with a continuous-release BCR pellet 
(2.3 mglday for 21 days) (dashed line) or a control pellet 
(solid line) 2 days before immunization (n  = 1 llgroup). The 
day after immunization appean on the X axis. and the corres- 
ponding mean clinical EAE score (& SEMI appears on the Y 
axis. Clinical EAE fcores were graded duib by a blinded inces- 
tigator. 
The effect on EAE of BCR pellets implanted 2 days 
before immunization is shown in the Figure and in 
Table 1. When compared with dummy-implant con- 
trols, BCR treatment reduced both the incidence of 
signs of EAE ( p  < 0.05, Fisher exact probability test) 
as well as the clinical EAE score ( p  < 0.001 Mann- 
Whitney U test). Two BCR-treated rats had signs of 
disease beginning 1 day after exhaustion of the BCR 
pellet. One of these rats had not had previous clinical 
signs of EAE. 
Proliferative studies of splenic lymphocytes har- 
vested from rats killed on day 10 after immunization 
revealed a pronounced reduction in mitogenic re- 
sponses both to the immunogen and to ConA in BCR- 
treated rats (Table 2). 
Immunization was associated with a greater than 
threefold rise in serum PRL levels (Table 3) .  BCR 
treatment effectively inhibited this rise in serum and 
reduced pituitary PRL content measured 10 days after 
immunization. 
Delayed Initiation of Bromocrz$tine Treatment 
Moderates Acute and Late Disease 
BCR pellets implanted 1 week after immunization 
were also effective in moderating the incidence of signs 
of acute EAE ( p  < 0.01, x2) and the peak clinical EAE 
score ( p  < 0.025, Mann-Whitney U )  (Table 4). Addi- 
tionally, a reduction in the incidence and severity of 
late disease was found in the BCR-treatment compared 
with the control-treatment group ( p  < 0.025) (see Ta- 
Table 2. Proliferative Responses of Pooled Splenic Lymphocytes from Control or BCR-Pellet-Implanted Rats (n = -//Group) 
Treatment Background 0.1% GPSC ConA (5 pgiml) 
Control 283,000 * 24,000 (SI = 377) 
BCR 149,000 +- 36,000 (SI = 87.6) 
Pellets were implanted 2 days before immunization for EAE and splenic lymphocytes harvested on day 10 after immunization. Results are 
expressed as counts per minute (mean t SEM) and as stimulation indces (SI) to guinea pig spinal cord homogenate (GPSC) or to Concanavalin 
A (ConA). See text for details. 
BCR = bromocriptine; EAE = experimental allergic encephalomyelitis. 
750 2 100 13,500 ? 800 (SI = 18) 
1,700 k 240 8,600 2 1,800 (SI = 5.1) 
Table 3. Prolactin b e h  (Mean f SEM) in Lewis Rats Immunized for EAE (n = 7IGroupi 
Day 4" Serum (ng/ml) Day lob Serum (ng/ml) Pituitary (Kglgland) Group 
Sham immunization 27 f 13 
Immunization 109 * 37' 
Control . . .  
BCR . . .  
>125 
36 -1- 12' 
. .  
126 * 14 
97 * 12 
"Serum PRL measurement 4 days after immunization. 
bSerum level and pituitary content of PRL 10 days after immunization. 
c p  < 0.01. 
EAE = experimental allergic encephalomyelitis; BCR = bromocriptine; PRL = prolactin. 
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Table 4. Effect of Late Initiation of BCR Treatment on the Course of EAE 
Acute EAE Late Disease 
Peak Chnical Peak Clinical 
EAE Score Neurological EAE Score Neurological Day of Onset Duration 
Treatment (Mean -+ SEM)a Signs Deaths (Mean 2 SEM)” Signs (Mean f SEM) (Mean f SEM) Deaths 
Control 1.7 ? 0.3 13/15 0 2.9 +- 0.6 8/8 22.4 2 0.5 6 2 O.Gb 2 
BCR 0.7 * 0.3‘ 7117d 0 1.2 2 0.4< 418C 22.6 f 0.7 5 t 0.6 0 
“Includes zero scores for unaffected rats 
’Excludes 2 rats that died during the late relapse 
‘p < 0 025 ,  Mann-Whitney LI test, Fisher exact probability test 
Acute EAE was assessed in rats in whch BCR or control pellets were implanted 7 or 8 days after immunization Iate disease was assessed in the rats that were 
treated on day 8 after m u w a t i o n  
BCR = bromocriptine, EAE = expermental aller@c encephalomyelitis 
$3 i 0 01, x2 test 
ble 4). It was again observed that 2 of 8 BCR-treated 
rats developed signs of late disease beginning 1 and 3 
days after exhaustion of the BCR pellet. 
Discussion 
These results indicate that BCR pretreatment of sus- 
ceptible Lewis rats resulted in substantial protection 
from acute EAE, and that protection was associated 
with a proportional decrease in splenic proliferative 
responses to both immunogen and to ConA. BCR 
treatment initiated 1 week after immunization, at a 
time after sensitization had occurred El 11, also inhib- 
ited acute EAE and, in addition, prevented late disease 
that typically occurs in female rats during the early 
recovery period 112, 131. Moreover, signs of EAE de- 
veloped in several rats after the BCR pellets were ex- 
hausted. These results indicate that BCR protection 
results at least in part from inhibition of the effector 
limb of the T-cell response in rat EAE. 
Protection was incomplete because nearly 50% of 
BCR-treated, immunized rats developed signs of EAE 
that were generally mild and consisted of a loss of tail 
tone or an unsteady gait. It is possible that higher dos- 
ages or more effective delivery of BCR might provide 
more complete inhibition of disease. This is suggested 
by the finding that suppressed but detectable serum 
PRL levels were present in BCR-treated rats. Addition- 
ally, the effects of BCR on the pathology of EAE at 
different stages during the disease course is interesting, 
and these studies are underway. 
It is likely that the effects of BCR in rat EAE are 
mediated by inhibition of PRL secretion. PRL suppres- 
sion achieved by other routes, for example, by the non- 
dopaminergic drug cysteamine or by hypophysectomy, 
also results in functional immunosuppression { 1-51. 
BCR does not bind rat lymphocytes 1141, and the im- 
munosuppressive properties of this drug are reversed 
by the administration of PRL E3-51. 
Previous work in other disease models also indicates 
that BCR might moderate ongoing autoimmunity. 
When mice are immunized with bovine type I1 colla- 
gen in CFA 4 to 8 weeks before pregnancy, they de- 
velop a high frequency of autoimmune arthritis during 
the postpartum period; in some mice, arthritic signs 
resolve during subsequent pregnancies and recrudesce 
after delivery [15}. Postpartum BCR treatment sup- 
presses the clinical exacerbation of postpartum joint 
disease { 151, consistent with the hypothesis that lacta- 
tional elevation of PRL levels contributes to recurrent 
arthritis months after the initial immunization. 
Under normal conditions, PRL is secreted episodi- 
cally, in pulses of varying size and duration, with high- 
est levels during the night in association with sleep 
1161. In addition to its underlying diurnal secretory 
rhythm, PRL is acutely secreted in response to stress 
E16, 171. In contrast to the effects of acute stress, 
chronic stress (or chronic adrenocorticoid treatment) 
inhibits PRL secretion ElS}. PRL is secreted in large 
amounts during the postpartum period, and is the most 
important hormonal stimulus for lactation in mammals 
[lo, 161. It might be predicted that in immunized ani- 
mals, “stress” hormones such as adrenocorticotropic 
hormone and PRL would be erratically stimulated as a 
result of nonspecific discomfort. Besedovsky and asso- 
ciates El91 and Saphier [201, however, have demon- 
strated that a coordinated pattern of hypothalamic 
neurochemical and neuroendocrine events occurs in 
concert with other aspects of the immune response; 
for example, hypothalamic noradrenergic activity is in- 
hibited at the peak of the immune response to sheep 
red blood cells, several days before the rise of plasma 
corticosterone levels. 
Neuroendocrine responses also occur in a stereotyp- 
ical, predictable pattern in EAE; corticosterone levels 
rise predictably just before the onset of paralysis, 
reaching peak levels at the time of maximum neurolog- 
ical disease [ 2  l}. The rise of corticosterone is an essen- 
tial homeostatic response because adrenalectomized 
animals invariably die within a few days of immuniza- 
tion. Adrenalectomy soon after the onset of EAE pro- 
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motes EAE relapses 1227, suggesting that release of 
endogenous glucocorticoids modulates both the initial 
and the recurrent phases of the disease. In the current 
experiments, the severity of EAE was reduced in rats 
implanted with control pellets 1 week after immuniza- 
tion, perhaps due to effects of acute corticosterone se- 
cretion imparted by ether anesthesia. 
There is little information regarding PRL secretion 
during immune responses, and thus, the current find- 
ings that serum PRL levels are elevated in rat EAE 
are particularly interesting. One recent report indicated 
that PRL levels of male rats are stimulated to 150% of 
control levels during the first 6 days after immunization 
with CFAIM. bouis [23]. In EAE, the rise in serum 
PRL. is likely a consequence of immunization and is 
not disease specific, but further studies will be required 
to clarify this point. One potential mechanism of 
PRL stimulation during immune responses involves 
lymphokine-mediated stimulation of PRL secretion 
through direct actions on the hypothalamus or pituitary 
1241. 
In humans, elevated serum PRL levels have been 
reported to follow cardiac transplantation and to be 
present in some patients with chronic idiopathic irido- 
cyclitis 125, 261. In the former condition, a high level 
of circulating PRL was believed to presage graft rejec- 
tion, and in the latter, a clinical response to BCR has 
been claimed. Previous studies indicate that there is an 
increased risk of attacks of multiple sclerosis in the 
postpartum period, a time of physiological PRL hyper- 
secretion 127-347. Other autoimmune diseases have 
been observed to occur almost uniquely (e.g., lympho- 
cytic hypophysitis) or more commonly (rheumatoid ar- 
thritis and myasthenia gravis) during the puerperium 
135, 361. Although the neuroendocrine regulation of 
immune homeostasis is undoubtedly complex, inhibi- 
tion of PRL secretion may thus represent a potential 
approach to the control of autoimmune disorders. 
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